Research to Prevent Blindness
Overview
Research to Prevent Blindness is a non-profit organization that supports eye research directed at the prevention, treatment, or eradication of all diseases that threaten vision by providing grants to scientists and medical institutions.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| AsclepiX Therapeutics | Nov 2018 | Grant | Co-investor |
| Gateway Photonics | - | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Research to Prevent Blindness based?
Research to Prevent Blindness is headquartered in New York City, New York, United States.
When was Research to Prevent Blindness founded?
Research to Prevent Blindness was founded in 1960.
How many portfolio companies does Research to Prevent Blindness have?
Research to Prevent Blindness has 3 portfolio companies in Caplight's dataset.
What are some companies in Research to Prevent Blindness's portfolio?
Portfolio companies visible on Caplight include AsclepiX Therapeutics, Gateway Photonics.
What was Research to Prevent Blindness's most recent investment shown here?
Research to Prevent Blindness's most recent investment in this portfolio sample was in AsclepiX Therapeutics in 2018.
What sectors does Research to Prevent Blindness focus on?
Research to Prevent Blindness focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech.
What company stages does Research to Prevent Blindness focus on?
Stage focus information for Research to Prevent Blindness is not publicly available.
What is Research to Prevent Blindness's AUM?
Research to Prevent Blindness's assets under management are estimated between $274.0M and $274.0M.